|
|
News Breaks | | | | September 11, 2012 | | 05:33 EDT |  | CTIC | Cell Therapeutics: European launch of Pixuvri for late-stage aggressive NHL
Cell Therapeutics, or CTI, announced the initiation of the commercial launch of Pixuvri in the European Union, or EU, with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, U.K. and the Netherlands in November 2012. CTI plans to expand availability to France, Italy and Spain as well as other European countries in 2013. Pixuvri was granted conditional marketing authorization by the European Commission in May 2012 and is the first medicinal product licensed in the E.U. to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma, or NHL. In the E.U., there are approximately 37,000 new cases of aggressive B-cell NHL every year.1,2 | |
|
News For CTIC From The Last 14 Days Check below for free stories on CTIC the last two weeks. |
|
|
| May 20, 2013 | | 05:47 EDT | | CTIC | Cell Therapeutics reports the G-BA issues final assessment report for Pixuvri
 Subscribe for More Information | |
|
|
|
|
|
|
